Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.

NCT01710605 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT01710605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01710605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.
Lead sponsor
Institut Curie
Phase
Phase 3
Overall status
Unknown status
Start date
February 29, 2012
Completion date
September 30, 2018
Enrollment
800 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ductal infiltrating metastatic breast cancer, hormone-receptors positive breast cancer